Neuralstem (CUR) Misses Q4 EPS by 1c

Neuralstem (NASDAQ: CUR) reported Q4 EPS of ($0.07), $0.01 worse than the analyst estimate of ($0.06).

Cash, cash equivalents and short-term investments on hand was approximately $7.6 million at March 31, 2015, compared to approximately $12.2 million at December 31, 2015. The decrease was primarily due to our ongoing operating expenses primarily related to preparations for the initiation of our NSI-189 Phase 2 clinical trial for the treatment of MDD.

For earnings history and earnings-related data on Neuralstem (CUR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c